100 patients will benefit from personalized medicine based on the most comprehensive tumor profiling solution
This project is the first prospective regional molecular profiling program that combines liquid and solid analyses aspiring to improve the lives of patients with metastatic cancer. The aim of this study is to assess the clinical utility of precision medicine for tailoring the management of metastatic cancer patients for whom no standard-of-care guidelines exist or official guidelines have been exhausted. In total 100 patients will benefit from personalized medicine based on the most comprehensive tumor profiling solution. The study will be conducted in different medical centers in the following countries: Lebanon, Jordan, Saudi Arabia and United Arab Emirates. The recruitment shall be completed by the end of December 2017.
While research has made great strides in recent decades to improve and significantly extend the lives of patients with early stage cancer, the needs of patients with advanced or metastatic disease have largely been ignored. Patients with metastatic cancer often arrive to a point in their clinical care when either the standard of care is ineffective or no standard of care therapy exists. Where “one-size-fits-all” approach to medicine, based on broad population averages, fails in finding a solution, Personalized Cancer Care can allow the individualization of therapy for further treatment. Molecular profiling can provide treatment options tailored to the molecular profile of patient’s tumor. Unfortunately, tissue biopsy is a one-time single-site sampling and can miss the dynamics of tumor clonal evolution during disease progression. The emerging liquid biopsy by circulating tumor DNA (ctDNA) can fill the gap, not only providing actionable information for decision-making prior to treatment, but also longitudinal surveillance during and after the treatment regimen to assess for patient response, drug resistance and cancer recurrence.
In this context, the MOCS will use OncoDNA’s solutions (OncoSTRAT&GO and OncoTRACE) to help identify potential therapeutic targets or unconsidered treatment options, to tailor the treatment, to monitor treatment and thus optimize the patient care. In total 100 patients from the Middle East region, including Lebanon, Jordan, Saudi Arabia and United Arab Emirates are expected to take part in the study. Four cohorts of 25 subjects each will be composed by: patients with advanced refractory ovarian cancer, patients with metastatic triple negative breast cancer, patients with cancer of unknown primary and patients with rare cancers.
“This prospective research is the first of its kind in this region. Cancer patients will have the opportunity to be screened with a state-of-the-art and unique solution that will identify the most adequate treatment options according to their condition. The study will surely bring cancer precision medicine up to the next level and will possibly give new perspectives to both patients and oncologists” says Fiona Demol, International Business Development Manager at OncoDNA.
If you are a medical doctor from the Middle East region and you would like to join the project, please contact the local coordinator of the study: Dr. Gilbert Karayakoupoglou (email@example.com)
Cryogene is a Lebanon-based leading diagnostics company driven to transform the future of healthcare in the Middle East through the power of molecular biology. Formed by a team of diverse experts, Cryogene focuses on offering world-class technologies from accredited diagnostic laboratories in Europe and USA into many countries in the Middle East. While educating physicians and patients, Cryogene connects healthcare professionals with the most recent, reliable genetic tests previously unavailable in that region. More information at www.cryogene.eu